← All stocks

Tvardi Therapeutics, Inc.

TVRD Net selling
CIK 0001346830 #4976 in the set updated 19 Sep 2026
Bought (120 mo)
$9.10M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$23.04M
$61.93K on a plan · $2.85M straight out of an exercise
Sold at will
$20.13M
150 of 174 sales
Net
−$13.94M
−$11.03M against sales at will

By person

22 insiders · 180 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
RHO Ventures VI LP entity
10% owner
$9.10M (1)
+$9.10M
3,568,057
$16.98M
+16.3%
CHALMERS DEREK T
President & CEO
$6.98M (41)
−$6.98M
991,405
$4.72M
−9.6%
Slagel Dean
Director
$6.47M (2)
−$6.47M
1,064,338
$5.07M
−19.0%
Menzaghi Frederique Ph.D.
CHIEF SCIENTIFIC OFF,SVP-R&D
$4.18M (37)
−$4.18M
167,247
$796.10K
+36.0%
Mohindru Mani
CFO & Chief Strategy Officer
$2.05M (7) scheduled
−$2.05M
17,441
$83.02K
Goncalves Joana
CHIEF MEDICAL OFFICER
$942.15K (27)
−$942.15K
53,365
$254.02K
Ives Jeffrey L.
Director
$746.12K (15) scheduled
−$746.12K
198,485
$944.79K
Terrillion Scott
SEC'Y; CHIEF COMPLIANCE & G.C.
$566.72K (19)
−$566.72K
7,190
$34.22K
Posner Christopher
PRESIDENT AND CEO
$427.39K (17)
−$427.39K
13,109
$62.40K
VOGELBAUM MARTIN
Director
$320.32K (3)
−$320.32K
3,479,064
$16.56M
+13.4%
Stauffer Joseph William
Chief Medical Officer
$230.35K (2)
−$230.35K
2,000
$9.52K
−85.1%
BAINS HARRISON M JR
Director
$65.16K (1)
−$65.16K
57,438
$273.40K
Reilly Thomas Charles
Chief Financial Officer
$51.41K (2)
−$51.41K
37,811
$179.98K
Maynard Ryan D
CHIEF FINANCIAL OFFICER
$2.91K (1) scheduled
−$2.91K
13,500
$64.26K
+146.0%
Wirk Shaheen
Director
267,355
$1.27M
Shiff Susan Ph.D.
Director
202,085
$961.92K
HALL WALLACE L JR
Director
202,044
$961.73K
von Moltke Lisa
Director
183,009
$871.12K
Boudreau Helen M
Director
150,647
$717.08K
Schoell Josef
Chief Financial Officer
50,000
$238.00K
+8.7%
Makara Richard
VP, Head of Accting;Controller
13,583
$64.66K
+123.3%
Tweardy Samuel David
10% owner
0
$0.00
−100.0%

No percentages here. This company's share count has moved by a factor of 12.0 over the window, from 4,573,606 to 54,855,514 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Menzaghi Frederique Ph.D.
6 Aug 2018
Sr VP-Research & Development
Exercised, kept
10,000
$2.25
$22.50K
CHALMERS DEREK T
25 Jan 2018
President & CEO
Exercised, kept
3,000
$6.00
$18.00K
Menzaghi Frederique Ph.D.
7 Nov 2017
Sr VP-Research & Development
Exercised, kept
20,000
$2.48
$49.60K
CHALMERS DEREK T
3 Nov 2017
President & CEO
Exercised, kept
20,000
$2.48
$49.60K
Schoell Josef
26 Jul 2017
Chief Financial Officer
Exercised, kept
4,000
$2.25
$9.00K

What was left out

Form 4 filings counted 297
Amendments (4/A) skipped 4
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 6
Sales straight out of an exercise 18
Sales at will 150
Transactions with no price 0
Shares from compensation/vesting 3,901,190
Sales filed before the plan box existed 131
History held since 10 Mar 2017